LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,416,101
تعداد دریافت فایل اصل مقاله11,291,800
Gong, Yan, Song, Lele, Ou, Lei, Lu, You-Yong, Huang, Xianyong, Zeng, Qiang. (1402). Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma. سامانه مدیریت نشریات علمی, 48(4), 401-413. doi: 10.30476/ijms.2022.95583.2705
Yan Gong; Lele Song; Lei Ou; You-Yong Lu; Xianyong Huang; Qiang Zeng. "Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma". سامانه مدیریت نشریات علمی, 48, 4, 1402, 401-413. doi: 10.30476/ijms.2022.95583.2705
Gong, Yan, Song, Lele, Ou, Lei, Lu, You-Yong, Huang, Xianyong, Zeng, Qiang. (1402). 'Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma', سامانه مدیریت نشریات علمی, 48(4), pp. 401-413. doi: 10.30476/ijms.2022.95583.2705
Gong, Yan, Song, Lele, Ou, Lei, Lu, You-Yong, Huang, Xianyong, Zeng, Qiang. Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma. سامانه مدیریت نشریات علمی, 1402; 48(4): 401-413. doi: 10.30476/ijms.2022.95583.2705

Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma

Iranian Journal of Medical Sciences
مقاله 7، دوره 48، شماره 4، مهر 2023، صفحه 401-413    اصل مقاله (4.17 M)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2022.95583.2705
نویسندگان
Yan Gong1؛ Lele Song2؛ Lei Ou1؛ You-Yong Lu3؛ Xianyong Huang1؛ Qiang Zeng* 1
1Health Management Institute, The Second Medical Center and National Clinical Research Center for Geriatric Disease, Chinese PLA General Hospital, Beijing, China
2Division of Cancer Early Screening, Genetron Health (Beijing) Technology Co. Ltd., Beijing, China
3Laboratory of Molecular Oncology, School of Oncology, Peking University, Beijing Cancer Hospital and Institute, Beijing, China
چکیده
Background: Pancreatic cancer is a malignancy with high mortality due to the difficulties in early detection. We investigated and compared the diagnostic and prognostic performance of several blood biomarkers, including microRNA-25 (miR-25), carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), and carbohydrate antigen 125 (CA125). 
Methods: A retrospective study was conducted at the Chinese People’s Liberation Army General Hospital from May 2014 to September 2018. Serum specimens were collected, and miR-25 expression levels were measured using real-time quantitative polymerase chain reaction. Serum CA19-9, CEA, and CA125 levels were measured using enzyme-linked immunosorbent assay (ELISA). Statistical analyses including nonparametric test, receiver operator characteristic (ROC) curves, Kaplan-Meier analysis, and subsequent log-rank test were performed with PRISM 5.0 software. Univariate and multivariate analyses were performed with the R software. P<0.05 was considered statistically significant.
Results: A total of 250 individuals were recruited, including 75 with pancreatic ductal adenocarcinoma (PDAC), 75 with benign lesions, and 100 healthy controls. miR-25, CA19-9, CEA, and CA125 exhibited an area under the curve (AUC) of 0.88, 0.91, 0.81, and 0.76 with a sensitivity of 78.7%, 74.7%, 37.3%, and 35.7% and specificity of 91.5%, 97.0%, 98.2%, and 98.3%, respectively. The combination of miR-25 and CA19-9 further increased the sensitivity to 93.3% with a specificity of 88.5%. Stage-dependent sensitivity was observed with CA19-9, CEA, and CA125. miR-25 levels significantly stratified the prognosis by median level (4,989.97 copies/mL). CA19-9, CEA, and CA125 levels significantly stratified the prognosis by median levels. Univariate and subsequent multivariate analyses identified tumor (T) stage, CA19-9, and CA125 as independent risk factors for PDAC prognosis.
Conclusion: The combination of miR-25 and CA19-9 significantly enhanced the detection sensitivity of PDAC. T stage, CA19-9, and CA125 levels were independent risk factors for PDAC prognosis.
کلیدواژه‌ها
Pancreatic neoplasm؛ PDAC؛ Screening؛ microRNA؛ Adenocarcinoma
سایر فایل های مرتبط با مقاله
مراجع
  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-34. doi: 10.3322/caac.21551. PubMed PMID: 30620402.
  2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913-21. doi: 10.1158/0008-5472.CAN-14-0155. PubMed PMID: 24840647.
  3. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115-32. doi: 10.3322/caac.21338. PubMed PMID: 26808342.
  4. Ge L, Pan B, Song F, Ma J, Zeraatkar D, Zhou J, et al. Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy. BMJ Open. 2017;7:e018175. doi: 10.1136/bmjopen-2017-018175. PubMed PMID: 29282264; PubMed Central PMCID: PMCPMC5770961.
  5. Nolen BM, Brand RE, Prosser D, Velikokhatnaya L, Allen PJ, Zeh HJ, et al. Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study. PLoS One. 2014;9:e94928. doi: 10.1371/journal.pone.0094928. PubMed PMID: 24747429; PubMed Central PMCID: PMCPMC3991628.
  6. Rahat B, Ali T, Sapehia D, Mahajan A, Kaur J. Circulating Cell-Free Nucleic Acids as Epigenetic Biomarkers in Precision Medicine. Front Genet. 2020;11:844. doi: 10.3389/fgene.2020.00844. PubMed PMID: 32849827; PubMed Central PMCID: PMCPMC7431953.
  7. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20:460-9. doi: 10.1016/j.molmed.2014.06.005. PubMed PMID: 25027972.
  8. Liu R, Chen X, Du Y, Yao W, Shen L, Wang C, et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem. 2012;58:610-8. doi: 10.1373/clinchem.2011.172767. PubMed PMID: 22194634.
  9. Zhang H, Zuo Z, Lu X, Wang L, Wang H, Zhu Z. MiR-25 regulates apoptosis by targeting Bim in human ovarian cancer. Oncol Rep. 2012;27:594-8. doi: 10.3892/or.2011.1530. PubMed PMID: 22076535.
  10. Wu T, Hu H, Zhang T, Jiang L, Li X, Liu S, et al. miR-25 Promotes Cell Proliferation, Migration, and Invasion of Non-Small-Cell Lung Cancer by Targeting the LATS2/YAP Signaling Pathway. Oxid Med Cell Longev. 2019;2019:9719723. doi: 10.1155/2019/9719723. PubMed PMID: 31316723; PubMed Central PMCID: PMCPMC6604298.
  11. Wang Z, Wang N, Liu P, Chen Q, Situ H, Xie T, et al. MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin. Oncotarget. 2014;5:7013-26. doi: 10.18632/oncotarget.2192. PubMed PMID: 25026296; PubMed Central PMCID: PMCPMC4196180 to disclose.
  12. ZiaSarabi P, Sorayayi S, Hesari A, Ghasemi F. Circulating microRNA-133, microRNA-17 and microRNA-25 in serum and its potential diagnostic value in gastric cancer. J Cell Biochem. 2019;120:12376-81. doi: 10.1002/jcb.28503. PubMed PMID: 30861177.
  13. Zhang J, Bai R, Li M, Ye H, Wu C, Wang C, et al. Excessive miR-25-3p maturation via N(6)-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Nat Commun. 2019;10:1858. doi: 10.1038/s41467-019-09712-x. PubMed PMID: 31015415; PubMed Central PMCID: PMCPMC6478927.
  14. Abel Y, Rederstorff M. Stem-Loop qRT-PCR-Based Quantification of miRNAs. Methods Mol Biol. 2021;2300:59-64. doi: 10.1007/978-1-0716-1386-3_6. PubMed PMID: 33792871.
  15. Yu Y, Tong Y, Zhong A, Wang Y, Lu R, Guo L. Identification of Serum microRNA-25 as a novel biomarker for pancreatic cancer. Medicine (Baltimore). 2020;99:e23863. doi: 10.1097/MD.0000000000023863. PubMed PMID: 33350781; PubMed Central PMCID: PMCPMC7769376.
  16. Global Burden of Disease Cancer C, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3:524-48. doi: 10.1001/jamaoncol.2016.5688. PubMed PMID: 27918777; PubMed Central PMCID: PMCPMC6103527.
  17. Deng T, Yuan Y, Zhang C, Zhang C, Yao W, Wang C, et al. Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis. Cell Physiol Biochem. 2016;39:1716-22. doi: 10.1159/000447872. PubMed PMID: 27639768.
  18. Dai X, Pang W, Zhou Y, Yao W, Xia L, Wang C, et al. Altered profile of serum microRNAs in pancreatic cancer-associated new-onset diabetes mellitus. J Diabetes. 2016;8:422-33. doi: 10.1111/1753-0407.12313. PubMed PMID: 25991015.
  19. Rustgi AK. Familial pancreatic cancer: genetic advances. Genes Dev. 2014;28:1-7. doi: 10.1101/gad.228452.113. PubMed PMID: 24395243; PubMed Central PMCID: PMCPMC3894408.
  20. Humphris JL, Johns AL, Simpson SH, Cowley MJ, Pajic M, Chang DK, et al. Clinical and pathologic features of familial pancreatic cancer. Cancer. 2014;120:3669-75. doi: 10.1002/cncr.28863. PubMed PMID: 25313458.
  21. Petersen GM. Familial Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am. 2015;29:641-53. doi: 10.1016/j.hoc.2015.04.007. PubMed PMID: 26226902; PubMed Central PMCID: PMCPMC4522044.
  22. McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24:4846-61. doi: 10.3748/wjg.v24.i43.4846. PubMed PMID: 30487695; PubMed Central PMCID: PMCPMC6250924.
  23. Ma ZY, Gong YF, Zhuang HK, Zhou ZX, Huang SZ, Zou YP, et al. Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management. World J Gastroenterol. 2020;26:2305-22. doi: 10.3748/wjg.v26.i19.2305. PubMed PMID: 32476795; PubMed Central PMCID: PMCPMC7243647.
  24. Weissman S, Takakura K, Eibl G, Pandol SJ, Saruta M. The Diverse Involvement of Cigarette Smoking in Pancreatic Cancer Development and Prognosis. Pancreas. 2020;49:612-20. doi: 10.1097/MPA.0000000000001550. PubMed PMID: 32433397; PubMed Central PMCID: PMCPMC7249487.
  25. Khadka R, Tian W, Hao X, Koirala R. Risk factor, early diagnosis and overall survival on outcome of association between pancreatic cancer and diabetes mellitus: Changes and advances, a review. Int J Surg. 2018;52:342-6. doi: 10.1016/j.ijsu.2018.02.058. PubMed PMID: 29535016.
  26. Chang JC, Kundranda M. Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma. Int J Mol Sci. 2017;18. doi: 10.3390/ijms18030667. PubMed PMID: 28335509; PubMed Central PMCID: PMCPMC5372679.
  27. Yang C, Cheng H, Luo G, Lu Y, Guo M, Jin K, et al. The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system. Eur J Surg Oncol. 2017;43:2112-8. doi: 10.1016/j.ejso.2017.07.010. PubMed PMID: 28802662.
  28. Gu YL, Lan C, Pei H, Yang SN, Liu YF, Xiao LL. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy. Asian Pac J Cancer Prev. 2015;16:6569-73. doi: 10.7314/apjcp.2015.16.15.6569. PubMed PMID: 26434876.
  29. Chen Y, Gao SG, Chen JM, Wang GP, Wang ZF, Zhou B, et al. Serum CA242, CA199, CA125, CEA, and TSGF are Biomarkers for the Efficacy and Prognosis of Cryoablation in Pancreatic Cancer Patients. Cell Biochem Biophys. 2015;71:1287-91. doi: 10.1007/s12013-014-0345-2. PubMed PMID: 25486903.
آمار
تعداد مشاهده مقاله: 828
تعداد دریافت فایل اصل مقاله: 590


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب